{
    "organizations": [],
    "uuid": "c09725da27a41de5b839f095e4169273dbb23345",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-approves-expanded-indication-f/brief-fda-approves-expanded-indication-for-truvada-idUSASO0004U7",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Approves Expanded Indication For Truvada",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - Gilead Sciences Inc:\n* U.S. FOOD AND DRUG ADMINISTRATION APPROVES EXPANDED INDICATION FOR TRUVADAÂ® (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE) FOR REDUCING THE RISK OF ACQUIRING HIV-1 IN ADOLESCENTS\n* GILEAD SCIENCES - U.S. FDA HAS APPROVED ONCE-DAILY ORAL TRUVADA TO REDUCE RISK OF SEXUALLY ACQUIRED HIV-1 IN AT-RISK ADOLESCENTS Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-16T00:55:00.000+03:00",
    "crawled": "2018-05-16T18:51:38.056+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "gilead",
        "science",
        "inc",
        "food",
        "drug",
        "administration",
        "approves",
        "expanded",
        "indication",
        "emtricitabine",
        "tenofovir",
        "disoproxil",
        "fumarate",
        "reducing",
        "risk",
        "acquiring",
        "adolescent",
        "gilead",
        "science",
        "fda",
        "approved",
        "oral",
        "truvada",
        "reduce",
        "risk",
        "sexually",
        "acquired",
        "adolescent",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}